Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

Lancet Infectious Diseases

Volumn 4, Issue 8, 2004, Pages 519-527

  Safdar, Nasia ^a   Handelsman, Jo ^b   Maki, Dennis G ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFOPERAZONE; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; KANAMYCIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN; UREIDOPENICILLIN;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HUMAN; META ANALYSIS; MORTALITY; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RASH; RETROSPECTIVE STUDY; REVIEW; RISK;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 4043059435     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(04)01108-9     Document Type: Review

References (75)

1. Maki DG. Risk factors for nosocomial infection in intensive care. Devices vs nature and goals for the next decade. Arch Intern Med. 149:1989;30-35
2. Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 9:1995;497-530
3. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med. 335:1996;1445-1453
4. Virk A, Steckelberg JM. Clinical aspects of antimicrobial resistance. Mayo Clin Proc. 75:2000;200-214
5. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM, Weinstein RA. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 23:1996;779-784
6. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes RP. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 24:1997;211-215
7. Sanders WE Jr, Sanders CC. Enterobacter spp: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev. 10:1997;220-241
8. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Crit Care Med. 29:2001;N75-81
9. Anonymous. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 to June 2002. Am J Infect Control 2002; 30: 458-475.
10. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 34:2002;634-640
11. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 162:2002;185-190
12. Shlaes DM. The clinical relevance of enterobacter infections. Clin Ther. 15:(suppl A):1993;21-28
13. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med. 29:(suppl 4):2001;N114-120
14. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore MH, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 28:1999;1128-1133
15. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 159:1999;1127-1132
16. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med. 103:1997;51-59
17. Barza M, Travers K. Excess infections due to antimicrobial resistance: the "attributable fraction" Clin Infect Dis. 34:(suppl 3):2002;S126-130
18. Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Update. 3:2000;247-255
19. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 87:1989;540-546
20. Feldman C, Smith C, Levy H, Ginsburg P, Miller SD, Koornhof HJ. Klebsiella pneumoniae bacteraemia at an urban general hospital. J Infect. 20:1990;21-31
21. Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 14:2000;293-319
22. Kaye KS, Kaye D. Multidrug-resistant pathogens: mechanisms of resistance and epidemiology. Curr Infect Dis Rep. 2:2000;391-398
23. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 11:1999;7-12
24. Calandra T, Cometta A. Antibiotic therapy for gram-negative bacteremia. Infect Dis Clin North Am. 5:1991;817-834
25. Bouza E, Munoz P. Monotherapy versus combination therapy for bacterial infections. Med Clinics of North Am. 84:2000;1357-1389
26. Rybak MJ, McGrath BJ. Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. Drugs. 52:1996;390-405
27. Shlaes DM, Bass SN. Combination antimicrobial therapy. Pediatr Clin North Am. 30:1983;121-134
28. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside- containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis. 2:2002;231-242
29. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 326:2003;1111
30. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996; 15: 1237-1248; discussion 1249-52.
31. Breslow NE, Day NE. Statistical methods in cancer research. In: Analysis of case-control studies. Vol 1. Lyon, France: International Agency for Research on Cancer; 1980.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:1997;629-634
33. McCue JD. Gram-negative bacillary bacteremia in the elderly: incidence, ecology, etiology, and mortality. J Am Geriatr Soc. 35:1987;213-218
34. McCue JD. Improved mortality in gram-negative bacillary bacteremia. Arch Intern Med. 145:1985;1212-1216
35. Tapper ML, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. J Infect Dis. 130:(suppl A):1974;S14-23
36. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 68:1980;344-355
37. Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 26:1984;870-875
38. Garcia de la Torre M, Romero-Vivas J, Martinez-Beltran J, Guerrero A, Meseguer M, Bouza E. Klebsiella bacteremia: an analysis of 100 episodes. Rev Infect Dis. 7:1985;143-150
39. Bouza E, Garcia de la Torre M, Erice A, Cercenado E, Loza E, Rodriguez-Creixems M. Serratia bacteremia. Diagn Microbiol Infect Dis. 7:1987;237-247
40. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 115:1991;585-590
41. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 41:1997;1127-1133
42. Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother. 36:1992;2639-2644
43. Mendelson MH, Gurtman A, Szabo S, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis. 18:1994;886-895
44. de Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med. 120:1994;834-844
45. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis. 2:1998;211-215
46. Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 17:1998;701-708
47. Kim BN, Ryu J, Kim YS, Woo JH. Retrospective analysis of clinical and microbiological aspects of Klebsiella oxytoca bacteremia over a 10-year period. Eur J Clin Microbiol Infect Dis. 21:2002;419-426
48. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 156:1996;2121-2126
49. Behre G, Link H, Maschmeyer G, et al. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients. Ann Hematol. 76:1998;73-80
50. McCabe WR, Jackson GG. Gram negative bacteremia. Arch Intern Med. 110:1962;92-100
51. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 244:1998;379-386
52. Kolleff MH. Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Med. 29:2003;147-149
53. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med. 27:(suppl 1):2001;S33-48
54. O'Grady NP, Barie PS, Bartlett JG, et al. Practice guidelines for evaluating new fever in critically ill adult patients. Clin Infect Dis. 26:1998;1042-1059
55. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol. 6:1987;234-244
56. Wade JC. Antibiotic therapy for the febrile granulocytopenic cancer patient: combination therapy versus monotherapy. Rev Infect Dis. 11:(suppl 7):1989;S1572-1581
57. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med. 80:1986;126-137
58. Giamarellou H, Zissis NP, Tagari G, Bouzos J. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 25:1984;534-536
59. Klastersky J, Hensgens C, Meunier-Carpentier F. Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial. J Infect Dis. 134:1976;S433-440
60. Klastersky J, Zinner SH. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis. 4:1982;294-301
61. Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis. 19:2000;915-925
62. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropaenia. Cochrane Database Syst Rev 2002: CD003038.
63. Comber KR, Basker MJ, Osborne CD, Sutherland R. Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrob Agents Chemother. 11:1977;956-964
64. Kluge RM, Standiford HC, Tatem B, et al. Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 6:1974;442-446
65. Yoshikawa TT, Shibata SA. In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 13:1978;997-999
66. Heineman HS, Lofton WM. Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro. Antimicrob Agents Chemother. 13:1978;827-831
67. Archer G, Fekety FR Jr. Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin. J Infect Dis. 136:1977;327-335
68. Gimeno C, Borja J, Navarro D, Valdes L, Garcia-Barbal J, Garcia-de-Lomas J. In vitro interaction between ofloxacin and cefotaxime against gram-positive and gram-negative bacteria involved in serious infections. Chemotherapy. 44:1998;94-98
69. Milatovic D, Wallrauch C. In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Eur J Clin Microbiol Infect Dis. 15:1996;688-693
70. Jenkins SG, Lewis JW. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens. Infection. 23:1995;154-161
71. Pohlman JK, Knapp CC, Ludwig MD, Washington JA. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. Diagn Microbiol Infect Dis. 26:1996;29-33
72. Ehrhardt AF, Sanders CC. Beta-lactam resistance amongst Enterobacter species. J Antimicrob Chemother. 32:(suppl B):1993;1-11
73. Sanders CC, Sanders WE Jr. Clinical importance of inducible beta-lactamases in gram-negative bacteria. Eur J Clin Microbiol. 6:1987;435-438
74. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy. 15:1995;279-291
75. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 42:1998;521-527